Table 4 Psychometric test performance at baseline and follow-up according to metabolic syndrome manifestations.
From: Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
Psychometric test | Controls (n = 30) | Patients (n = 63) | Baseline | 3-month follow-up | 6-month follow-up | ||||
|---|---|---|---|---|---|---|---|---|---|
No MHE (n = 31) | MHE (n = 32) | Non metabolic manifestation (n = 11) | Metabolic manifestation (n = 21) | Non metabolic manifestation (n = 11) | Metabolic manifestation (n = 21) | Non metabolic manifestation (n = 11) | Metabolic manifestation (n = 21) | ||
Cognitive test | |||||||||
Stroop test | |||||||||
Congruent task | 115 (2.6) | 105 (3.2)* | 71 (4)***/ααα | 72 (9)***/αα | 70 (4)***/ααα | 89 (7)***/αα | 70 (4)***/ααα/β | 85 (7)***/αα | 78(6)***/ααα |
Neutral task | 83 (2.4) | 75 (2.3)* | 56 (3)***/ααα | 62 (6)***/α | 53 (2)***/ααα | 66 (4)** | 55 (2)***/ααα/β | 61 (3)***/α | 61(4)***/αα |
Incongruent task | 46 (1.5) | 41 (2)* | 29 (2)***/ααα | 31 (5)***/α | 28 (2)***/ααα | 34 (2)***/α | 32 (2)***/αα | 32 (3)***/α | 36 (3)** |
d2 test | |||||||||
Total responses | 402 (16) | 337 (13)** | 244 (17)***/ααα | 276 (19)***/α | 230 (22)***/ααα | 317 (20)** | 245 (23)***/ααα/β | 304 (17)**/∂ | 266(8)***/α |
Total correct | 150 (6.4) | 130 (6)* | 83 (7)***/ααα | 95 (6)***/αα | 78 (10)***/ααα | 107 (13)** | 93 (10)***/αα/∂ | 103 (9)**/α | 100(4)***/α |
Omission errors | 17 (2.6) | 12 (2) | 21 (4) | 24 (10) | 20 (5) | 28 (7) | 11 (2) | 25 (11) | 11(3) |
Commission errors | 1 (0.2) | 4 (1)* | 11 (3)**/α | 12 (6) | 10 (3)* | 5 (3) | 4 (2) | 9 (6) | 7(2)* |
Total effectiveness | 371 (19) | 298 (16)** | 214 (16)***/αα | 241 (10)** | 202 (23)***/αα | 284 (25)* | 230 (25)***/α | 270 (14)* | 149(1)** |
Concentration index | 146 (6.7) | 126 (6)* | 72 (9)***/ααα | 83 (11)***/αα | 68 (11)***/ααα | 102 (14)** | 89 (11)***/α/∂ | 94 (14)**/α | 94 (15)** |
Oral SDMT | 50 (1.3) | 44 (2)** | 23 (2)***/ααα | 32 (2)***/ααα | 19 (3)***/ααα/ββ | 36 (2)***/α | 24 (3)***/ααα/ββ | 34 (3)***/α | 31 (4)***/αα |
Digit Span | 16 (0.8) | 13 (0.5)** | 10 (0.5)***/αα | 12 (1)** | 10 (1)***/ααα/β | 13 (1) | 10 (1)***/ααα/β | 14 (2) | 11 (1)** |
Letter-number sequencing | 10 (0.4) | 8 (0.5)** | 5 (0.5)***/ααα | 7 (1)** | 4 (1)***/ααα/ββ | 7 (1)** | 6 (1)***/αα | 6 (1)** | 5 (1)***/αα |
Motor coordination tests | |||||||||
Bimanual coordination | 1.9 (0.03) | 2.3 (0.1)*** | 3.7 (0.4)***/αα | 2.9 (0.2)**/αα | 3.9 (0.5)***/αα | 2.6 (0.1)***/α | 3.3 (0.2)***/ααα/ββ | 2.7 (0.1)**/α | 3.3 (0.3)***/αα |
Visuo-motor coordination | 2.4 (0.1) | 3 (0.1)*** | 3.9 (0.2)***/ααα | 3 (0.2)*** | 4 (0.2)***/ααα/β | 3.4 (0.3)*** | 4.1 (0.4)***/αα | 3.4 (0.2)*** | 3.9 (0.4)***/α |
